Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002359 · ClinicalTrials.gov registry record · Phase 3
A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega
A Phase 3 study of HIV Infections, sponsored by The Immune Response Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,000
- Enrollment target
- 20
- Study locations
NCT00002359: Completed Phase 3 study of HIV Infections, sponsored by The Immune Response Corporation.
NCT00002359 is a Phase 3 study of HIV Infections that has completed, run by The Immune Response Corporation. The registered enrollment target is 3,000 participants, above the 440-participant average among 542 other HIV Infections trials with a reported enrollment target (582% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002359, a Phase 3 study of HIV Infections, has completed, sponsored by The Immune Response Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
To determine the effect of HIV-1 immunogen (Remune) on AIDS-free survival, defined as the time prior to development of an AIDS-defining condition or death.
Conditions Studied
Interventions
- BIOLOGICAL HIV-1 Immunogen
Study Locations (20)
California
- Ctr for Special Immunology - Irvine
- Jeffrey Goodman Special Care Clinic - Los Angeles
- Kraus Med Partners - Los Angeles
- Cedars Sinai Med Ctr - Los Angeles
- AIDS Community Research Consortium - Redwood City
Florida
- North Broward Hosp District - Fort Lauderdale
- Ctr for Special Immunology - Miami Beach
- The Coleman Institute - North Miami
- Clinical Pharmacology Services - Tampa
District of Columbia
- Whitman Walker Clinic Inc - Washington D.C.
- Anderson Clinical Research - Washington D.C.
- George Washington Univ Med Ctr - Washington D.C.
Illinois
- Rush Med Ctr - Chicago
- Chicago AIDS Research Alliance - Chicago
- Ctr for Special Immunology - Chicago
Arizona
- Phoenix Body Positive - Phoenix
Georgia
- AIDS Research Consortium of Atlanta - Atlanta
Indiana
- Community Hosp Indianapolis - Indianapolis
Kansas
- UKSM-W Med Practice Association - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002359
The ClinicalTrials.gov registry entry for NCT00002359 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 440-participant average among 542 other HIV Infections trials with a reported enrollment target (582% higher). The listed sponsor is The Immune Response Corporation, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which HIV-1 Immunogen is the first listed.
NCT00002359 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00002359 about?
NCT00002359 is a clinical study titled "A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega". To determine the effect of HIV-1 immunogen (Remune) on AIDS-free survival, defined as the time prior to development of an AIDS-defining condition or death.
What is the current status of trial NCT00002359?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,000 participants.
What conditions does trial NCT00002359 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002359?
The interventions under investigation include: HIV-1 Immunogen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002359?
This trial is sponsored by The Immune Response Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002359 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.